switching glp 1 agonists Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance The GLP-1 Agonists and Obesity:

Phenotypic outcomessuch as improved insulin sensitivity or enhanced thermogenesismay provide more robust translational anchors than circulating peptide levels alone

Lilly is following this with retatrutide, a triple agonist, which has completed phase 2 trials for treating obesity and cardiovascular disease

Inhibitors of GH Secretion Several factors can suppress GH release: Somatostatin (also from the hypothalamus) directly inhibits GH secretion Hyperglycemia (high blood sugar) Elevated IGF-1 levels (negative feedback) Chronic stress or high cortisol levels Poor sleep and circadian disruption GHRH Analogues: Peptides That Mimic Natural Signals Several peptides have been developed to mimic the action of GHRH, improving GH release in a physiologically balanced way

And I think oftentimes by doing something like that, you can think about it and you can realize, oh, what I really cant do is Im not agile anymore

doi: 10.1203/00006450-199606000-00025

As your body adjusts to a stable dose, some of the reward-system dampening may moderate